Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Accumulated Depreciation (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Accumulated Depreciation data on record, last reported at $1.7 million in Q3 2025.

  • For Q3 2025, Accumulated Depreciation changed N/A year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, changed N/A, while the annual FY2023 figure was $1.2 million, 34.8% up from the prior year.
  • Accumulated Depreciation reached $1.7 million in Q3 2025 per BTAI's latest filing, up from $1.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $1.7 million in Q3 2025 and bottomed at $763000.0 in Q2 2022.
  • Average Accumulated Depreciation over 4 years is $1.2 million, with a median of $1.1 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation: surged 35.78% in 2023, then surged 30.12% in 2024.
  • A 4-year view of Accumulated Depreciation shows it stood at $885000.0 in 2022, then soared by 34.8% to $1.2 million in 2023, then rose by 12.99% to $1.3 million in 2024, then increased by 28.19% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $1.7 million in Q3 2025, $1.6 million in Q1 2025, and $1.3 million in Q2 2024.